Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Growth Officer | May 17, 2021 | May 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date May 17, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2031-05-17 | Direct | 100,000 |
Reported balance
After 2021-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-17 · Grant · Acquired 100,000 · Balance 100,000 F1: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2021 Filed May 20, 2021 16:38 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-21-034432 · doc4.xml · derivative · entry 1 Cuvelier Chris · CIK 0001863255 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-05-17 F1 · derivative.exercise_date: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.